ClinicalTrials.gg
Not yet recruitingNCT06927245Updated Aug 11, 2025

Use of the PTEye Device to Reduce Inadvertent Parathyroidectomy During Thyroid Surgery

An interventional study of PTeye Device in Thyroid Surgery, Inadvertent Parathyroidectomy and Enlarged Thyroid, sponsored by ProMedica Health System. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by ProMedica Health System · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Inadvertent Parathyroidectomy (IP) during thyroid surgery may lead to transient or permanent hypoparathyroidism and hypocalcemia, which represents significant morbidity. Patients that suffer from IP and its clinical consequences often require longer duration of hospitalization and additional inpatient treatment and prescription medications. ProMedica performs a large number of endocrine procedures, so the use of novel technology to aid in the intra operative identification of parathyroid glands may ultimately offer decreased morbidity to patients.

The goal of this study is to find out if using the PTEye device (a device that uses infrared light to find the Parathyroid gland) lowers the amount of times a surgeon accidentally takes out the Parathyroid gland while trying to take out the Thyroid gland in surgery.

Read the detailed description

Inadvertent Parathyroidectomy (IP) during thyroid surgery may lead to transient or permanent hypoparathyroidism and hypocalcemia, which represents significant morbidity. Patients that suffer from IP and its clinical consequences often require longer duration of hospitalization and additional inpatient treatment and prescription medications. ProMedica performs a large number of endocrine procedures, so the use of novel technology to aid in the intra operative identification of parathyroid glands may ultimately offer decreased morbidity to patients.

The investigators plan to prospectively enroll 25 patients undergoing either thyroid lobectomy or total thyroidectomy. The surgeries will be performed by study approved surgeons. All surgeries will take place over a 90 day period beginning at the receipt of the PTEye device. All subjects will be consented pre-operatively for enrollment in the study, including consent for use of the PTeye device. Subjects undergoing a planned parathyroidectomy, Cistrunk procedure, repeat neck surgery, or neck dissection will not be included in this particular study.

Subjects will not have any changes in their pre-surgical procedure. Subjects will follow typical standard of care procedures for surgery. Once the subject is in surgery, the surgeon will use the PTeye device to identify the parathyroid gland. Using the disposable probe to make contact with the tissue, the surgeon will scan the thyroid for a baseline reading. Once the surgeon has established a baseline, they are able to use the device to confirm whether the tissue they identified is parathyroid tissue. The device will make a noise when it detects parathyroid tissue. Other than the use of the PTeye device, the surgeons will follow standard of care procedures to perform the surgery. The subject will follow standard of care post-operative procedures and will not be required to attend any additional appointments (other than those scheduled per standard of care).

The investigators will extract multiple data points from these 25 subjects. The primary endpoint will be the rate of inadvertent parathyroidectomy. This will be identified by review of surgical pathology reports for parathyroid tissue. Secondary endpoints include the number of frozen sections sent, number of autotransplantations of parathyroid tissue performed, operative times, and post operative Parathyroid Hormone and Calcium levels. These data points will be collected by chart review. Each subject will follow up two weeks post operatively, per standard of care procedure. We plan to follow patients for one month post operatively to monitor for any pertinent hospital readmissions by performing a chart review of the patient.

02

Conditions studied

  • Thyroid Surgery
  • Inadvertent Parathyroidectomy
  • Enlarged Thyroid

Browse trials for

Keywords

  • PTEye
  • Total Thyroidectomy
  • Thyroid Lobectomy
  • Intraoperative Autofluorescence Imaging
  • Inadvertent Parathyroidectomy
  • Inadvertent Parathyroid Removal
03

In context

Goiter

66 studies on the registry are indexed under Goiter; 11 are open to participants now.

This study's planned enrollment of 25 is below the median of 100 across 42 interventional studies indexed under Goiter.

Browse Goiter studies →

Lead sponsor

ProMedica Health System is the lead sponsor of 15 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing either a total thyroidectomy or a thyroid lobectomy
  • Patients must be 18 years old or older
  • Patient needs to be operated on by a study approved surgeon

Exclusion criteria

Exclusion Criteria:

  • Under 18 years old
  • Receiving a planned parathyroidectomy, Cistrunk procedure, repeat neck surgery, or neck dissection
  • Receiving surgery from a non-approved surgeon
  • Pregnant at time of procedure
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Patients receiving Thyroid Surgery

    The experimental treatment group that is having either a Total Thyroidectomy or a Thyroid Lobectomy procedure done will have the PTEye device used in surgery to identify their Parathyroid Gland through autofluorescence.

    Device: PTeye Device

Interventions

  • DevicePTeye Device

    Near infrared stimulation of parathyroid tissue using light at a wavelength of approximately 690 - 770 nm results in autofluorescence of parathyroid tissue. Near infrared autofluorescence detection devices, such as PTEye have been developed with probe-based methods, displaying quantitative real-time information to aid surgeons in detection of parathyroid tissue relative to surrounding tissue.

    Also known as: Intraoperative Autofluorescence Imaging

06

What researchers measure

Primary outcomes

  1. Rate of Inadvertent Parathyroidectomy

    The aim of this study is to establish the rate of inadvertent parathyroidectomy during thyroid surgery when the PTeye near-infrared device is used to aid with intraoperative identification of the parathyroid gland.

    Time frame: From enrollment to one month after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06927245
Lead sponsor
ProMedica Health System
Responsible party
Joseph Sferra (Professor, Department of Surgery, ProMedica Health System) — Principal investigator
First posted
Apr 15, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Nov 30, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Aug 11, 2025

Study contacts

Leah Stevenson, MS
Contact
Leah.Stevenson@promedica.org
(419) 291-3491
Dawn Muskiewicz, MS
Contact
Dawn.Muskiewicz@promedica.org
(419) 291-7517

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion